Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value.

about

SABCS 2017 pathology: from bench to bedside

P2860

Q58775916-D5311608-D836-43A0-9208-0368A304CA65

P2860

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value.

Item

http://www.wikidata.org/entity/Q49622309

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Neoadjuvant palbociclib on ER+ ...... ponse and EndoPredict's value.

@en

Neoadjuvant palbociclib on ER+ breast cancer

@nl

type

Item

label

Neoadjuvant palbociclib on ER+ ...... ponse and EndoPredict's value.

@en

Neoadjuvant palbociclib on ER+ breast cancer

@nl

prefLabel

Neoadjuvant palbociclib on ER+ ...... ponse and EndoPredict's value.

@en

Neoadjuvant palbociclib on ER+ breast cancer

@nl

P1476

Neoadjuvant palbociclib on ER+ ...... ponse and EndoPredict's value.

@en

P2093

Christopher Y C Chow

http://www.w3.org/2001/XMLSchema#string

Louis W C Chow

http://www.w3.org/2001/XMLSchema#string

Masakazu Toi

http://www.w3.org/2001/XMLSchema#string

Satoshi Morita

http://www.w3.org/2001/XMLSchema#string

Wai-Kuen Ng

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Truncating mutations of RB1CC1 in human breast cancer

Molecular cloning and characterization of a novel retinoblastoma-binding protein

Requirement for CDK4 kinase function in breast cancer

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Regulation of hormonal therapy resistance by cell cycle machinery.

Tumor suppressor genes in breast cancer.

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

P304

123-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-17-0396

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29158285

http://www.w3.org/2001/XMLSchema#string

P932

5763422

http://www.w3.org/2001/XMLSchema#string

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value.

about

P2860

P2860

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932